Cian Healthcare Limited has received listing approval from BSE Limited for 2,37,50,000 equity shares worth ₹23.75 crores issued to promoters on preferential basis. The company filed a regulatory disclosure on March 21, 2026, confirming receipt of BSE's listing approval letter dated March 20, 2026, following the earlier board-approved equity allotment completed on March 16, 2026.

BSE Listing Approval and Trading Formalities

BSE Limited granted listing approval for 2,37,50,000 fully paid-up equity shares at face value of ₹10 each, bearing distinctive numbers from 1250001 to 2500000. The approval was communicated through reference number LOD/PREF/TS/FIP/4134/2025-26 dated March 20, 2026. The company must now complete requisite trading formalities and credit shares to respective demat accounts of shareholders.

Promoter Shareholding Structure

The preferential allotment establishes a clear promoter structure with three key stakeholders receiving the allocated shares. The distribution maintains the previously announced shareholding pattern with Ananta Medicare Limited emerging as the largest promoter.

The allotment increased the company's equity share capital from ₹1.25 crores to ₹25.00 crores, with the combined promoter group holding 95% of the company's equity.

Regulatory Compliance and Trading Requirements

BSE has specified several compliance requirements before granting trading approval. The company must file confirmation letters from NSDL/CDSL regarding crediting shares to beneficiary accounts and admitting capital to the depository system. Additionally, the company must ensure compliance with Regulation 167 of SEBI (ICDR) Regulations and file shareholding pattern in XBRL mode under Regulation 31(1)(c) of SEBI LODR Regulations, 2015.

NCLT Resolution Plan Background

This development follows the National Company Law Tribunal Mumbai Bench-VI's approval of the resolution plan on December 18, 2025. The plan was submitted by Mr. Pradeep Kumar Jain as the Successful Resolution Applicant under the Insolvency and Bankruptcy Code, 2016. The company had previously received in-principle approval on March 11, 2026, for the preferential issue.

Pradeep Kumar Jain had earlier filed comprehensive SEBI disclosures under Regulation 29(1) and Regulation 10(6) on March 17 and March 18, 2026, respectively, confirming his acquisition of 47,50,000 equity shares worth ₹4,75,00,000 through the preferential allotment.

Company Operations and Market Position

Cian Healthcare Limited operates as an ISO 9001:2015 and WHO GMP certified pharmaceutical company with its registered office in Pune, Maharashtra. The company maintains corporate operations in New Delhi and manufacturing facilities in Haridwar, Uttarakhand. The company trades on BSE Limited under scrip code 542678 with trading symbol CHCL.

Rajesh Jain has filed a regulatory disclosure with BSE Limited regarding his substantial acquisition of shares in Cian Healthcare Limited, completing the formal compliance requirements under SEBI Takeover Regulations. The disclosure, submitted on March 18, 2026, provides comprehensive details of his 52,50,000 equity share acquisition through an NCLT-approved resolution plan.

SEBI Regulatory Compliance

The acquisition triggered mandatory disclosure requirements under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Rajesh Jain's filing with BSE Limited confirms his compliance with regulatory obligations following the share allotment completed on March 16, 2026.

Acquisition Structure and Details

The share acquisition was executed through preferential allotment pursuant to a resolution plan approved by the National Company Law Tribunal, Mumbai Bench, on December 18, 2025. Rajesh Jain acquired 52,50,000 fully paid-up equity shares at face value of INR 10.00 per share, totaling INR 5,25,00,000.

Consolidated Shareholding Pattern

Following the acquisition, the promoter group's consolidated holding has reached 95% of Cian Healthcare's total equity share capital. The group includes Rajesh Jain as the acquirer, along with persons acting in concert - Ananta Medicare Limited and Pradeep Kumar Jain.

Corporate Restructuring Impact

The acquisition represents a significant milestone in Cian Healthcare's corporate restructuring under the NCLT-approved resolution plan. The transaction benefits from exemption provisions under SEBI regulations, specifically Regulation 10(1)(da), which covers acquisitions made pursuant to approved resolution plans.

The filing confirms Cian Healthcare's listing status on BSE Limited and establishes the new ownership structure following the successful implementation of the resolution plan approved by the Mumbai Bench of the National Company Law Tribunal.